Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $490.70, for a total value of $1,962,800.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $63,791. This trade represents a 96.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Up 1.1%

Shares of United Therapeutics stock opened at $493.99 on Friday. The firm has a market cap of $21.27 billion, a PE ratio of 18.72, a price-to-earnings-growth ratio of 4.90 and a beta of 0.86. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $496.73. The business’s fifty day simple moving average is $457.81 and its 200-day simple moving average is $374.43.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the company earned $6.39 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on UTHR. Bank of America increased their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Royal Bank Of Canada upped their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company lifted their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research note on Monday, December 8th. Finally, UBS Group raised their target price on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. AQR Capital Management LLC grew its position in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after buying an additional 364,713 shares in the last quarter. Invesco Ltd. grew its holdings in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares in the last quarter. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $317,617,000. Assetmark Inc. raised its holdings in shares of United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after purchasing an additional 197,384 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after purchasing an additional 4,145 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.